Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals
- 449 Downloads
Recent studies identified that metabolically abnormal non-obese phenotype is a risk factor for cardiovascular diseases. However, little is known about risk factor for progression from metabolically healthy non-overweight to metabolically abnormal phenotype. We hypothesized that fatty liver had a clinical impact on progression from metabolically healthy non-overweight to metabolically abnormal phenotype.
In this retrospective cohort study, 14,093 Japanese (7557 men and 6736 women), who received the health-checkup program from 2004 to 2012, were enrolled. Overweight and obesity were defined as body mass index 23.0–25.0 and ≥25.0 kg/m2. Four metabolic factors (impaired fasting glucose, hypertension, hypertriglyceridemia and low high density lipoprotein-cholesterol concentration) were used for definition of metabolically healthy (less than two factors) or metabolically abnormal (two or more). We divided the participants into three groups: metabolically healthy non-overweight (9755 individuals, men/women = 4290/5465), metabolically healthy overweight (2547 individuals, 1800/747) and metabolically healthy obesity (1791 individuals, 1267/524). Fatty liver was diagnosed by ultrasonography.
Over the median follow-up period of 5.3 years, 873 metabolically healthy non-overweight, 512 metabolically healthy overweight and 536 metabolically healthy obesity individuals progressed to metabolically abnormal. The adjusted hazard risks of fatty liver on progression were 1.49 (95% confidence interval 1.20–1.83, p = 0.005) in metabolically healthy non-overweight, 1.37 (1.12–1.66, p = 0.002) in metabolically healthy overweight and 1.38 (1.15–1.66, p < 0.001) in metabolically healthy obesity, after adjusting for age, sex, alcohol, smoking, exercise, impaired fasting glucose, hypertension, hypertriglyceridemia, low high density lipoprotein-cholesterol concentration, and abdominal obesity.
Fatty liver is an independent risk factor for progression from metabolically healthy status to metabolically abnormal phenotype, even in non-overweight individuals.
KeywordsNon-alcoholic fatty liver disease Metabolic syndrome Insulin resistance Obesity Lean
We thank all of the staff members in the medical health checkup center at Murakami Memorial Hospital.
Y.H. designed and conducted the study, researched, analyzed and interpreted the data, and wrote the manuscript; M.H. designed and conducted the study, researched and interpreted the data, and reviewed and edited the manuscript. T.F., A.O. and T.K. researched and interpreted the data, and reviewed the manuscript. M.F. designed and conducted the study, researched and interpreted the data, and reviewed the manuscript. All authors have approved the final draft submitted.
Compliance with ethical standards
Conflict of interest
M. Fukui has received grant and research support from AstraZeneca plc, Astellas Pharma Inc., Bristol-Myers Squibb K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Company Ltd., Kowa Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Nippon Chemiphar Company Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Terumo Co. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. M. Fukui, his immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. M. Fukui received no current funding for this study and this does not alter their adherence to all of the journal policies on sharing data and materials. The remaining authors declare that they have no competing interests.
The study was conducted in accordance with the Declaration of Helsinki, and an independent ethics committee.
Informed consent was obtained from all individual participants included in the study.
- 5.Y. Heianza, Y. Arase, H. Tsuji, K. Fujihara, K. Saito, S.D. Hsieh, S. Tanaka, S. Kodama, S. Hara, H. Sone, Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). J. Clin. Endocrinol. Metab. 99, 2952–2960 (2014)CrossRefGoogle Scholar
- 6.J. Zhang, H. Jiang, J. Chen, Combined effect of body mass index and metabolic status on the risk of prevalent and incident chronic kidney disease: a systematic review and meta-analysis. Oncotarget. in press. (2016). doi: 10.18632/oncotarget.10915
- 8.R. Dobson, M.I. Burgess, V.S. Sprung, A. Irwin, M. Hamer, J. Jones, C. Daousi, V. Adams, G.J. Kemp, F. Shojaee-Moradie, M. Umpleby, D.J. Cuthbertson, Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int. J. Obes. 40, 153–161 (2016)CrossRefGoogle Scholar
- 13.European Association for the Study of the Liver (EASL).; European Association for the Study of Diabetes (EASD).; European Association for the Study of Obesity (EASO)., EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016)Google Scholar
- 16.G. Musso, R. Gambino, J.H. Tabibian, M. Ekstedt, S. Kechagias, M. Hamaguchi, R. Hultcrantz, H. Hagström, S.K. Yoon, P. Charatcharoenwitthaya, J. George, F. Barrera, S. Hafliðadóttir, E.S. Björnsson, M.J. Armstrong, L.J. Hopkins, X. Gao, S. Francque, A. Verrijken, Y. Yilmaz, K.D. Lindor, M. Charlton, R. Haring, M.M. Lerch, R. Rettig, H. Völzke, S. Ryu, G. Li, L.L. Wong, M. Machado, H. Cortez-Pinto, K. Yasui, M. Cassader, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 11, e1001680 (2014)CrossRefPubMedCentralGoogle Scholar
- 18.M. Hamaguchi, T. Kojima, N. Takeda, C. Nagata, J. Takeda, H. Sarui, Y. Kawahito, N. Yoshida, A. Suetsugu, T. Kato, J. Okuda, K. Ida, T. Yoshikawa, Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 13, 1579–1584 (2007)CrossRefPubMedCentralGoogle Scholar
- 23.M. Hamaguchi, N. Takeda, T. Kojima, A. Ohbora, T. Kato, H. Sarui, M. Fukui, C. Nagata, J. Takeda, Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J. Gastroenterol. 18, 1508–1516 (2012)CrossRefPubMedCentralGoogle Scholar
- 28.Y. Fukuda, Y. Hashimoto, M. Hamaguchi, T. Fukuda, N. Nakamura, A. Ohbora, T. Kato, T. Kojima, M. Fukui, Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. Liver Int. 36, 713–720 (2016)CrossRefPubMedCentralGoogle Scholar
- 36.M. Hamaguchi, T. Kojima, Y. Itoh, Y. Harano, K. Fujii, T. Nakajima, T. Kato, N. Takeda, J. Okuda, K. Ida, Y. Kawahito, T. Yoshikawa, T. Okanoue, The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am. J. Gastroenterol. 102, 2708–2715 (2007)CrossRefGoogle Scholar
- 46.T. Fukuda, M. Hamaguchi, T. Kojima, K. Mitsuhashi, Y. Hashimoto, A. Ohbora, T. Kato, N. Nakamura, M. Fukui, Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men. Eur. J. Gastroenterol. Hepatol. 28, 1443–1449 (2016)CrossRefGoogle Scholar
- 48.N. Di Daniele, L. Petramala, L. Di Renzo, F. Sarlo, D.G. Della Rocca, M. Rizzo, V. Fondacaro, L. Iacopino, C.J. Pepine, A. De Lorenzo, Body composition changes and cardiometabolic benefits of a balanced Italian Mediterranean diet in obese patients with metabolic syndrome. Acta Diabetol. 50, 409–416 (2013)CrossRefGoogle Scholar
- 49.G. Merra, S. Gratteri, A. De Lorenzo, S. Barrucco, M.A. Perrone, E. Avolio, S. Bernardini, M. Marchetti, L. Di Renzo, Effects of very-low-calorie diet on body composition, metabolic state, and genes expression: a randomized double-blind placebo-controlled trial. Eur. Rev. Med. Pharmacol. Sci. 21, 329–345 (2017)PubMedGoogle Scholar